Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
MUbio
Carcinoma Associated Antigen Monoclonal Antibody (175F4)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MUB2007P
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG1
分类
Monoclonal
类型
Antibody
克隆号
175F4
抗原
Carcinoma ass. Antigen
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS
内含物
0.09% sodium azide
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
175F4, which, originally, has been raised anti the Human mammary carcinoma cell line (Zr-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins.
The antibody may be stored at 4°C. For prolonged storage prepare appropriate aliquots and store at or below -20°C. Prior to use, an aliquot is thawed slowly in the dark at ambient temperature, spun down again and used to prepare working dilutions by adding sterile phosphate buffered saline (PBS, pH 7.2). Repeated thawing and freezing should be avoided. Working dilutions should be stored at 4°C, not refrozen, and preferably used the same day. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance or the concentration of the product.
靶标信息
The chance of cure and choice of therapy for squamous carcinomas of the head and neck depend largely on the extent of disease, as assessed clinically by inspection,palpation and radiography. Since treatment failures are in part due to clinically undetected metastasis at the time of treatment, there is a need for more specific methods of tumor detection. Attempts to develop antibodies recognizing tumour-associated antigens have, in the case of carcinomas, resulted in the isolation of a large number of antibodies reactive with high-molecular-weight glycoproteins.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
